Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. (Q54645772)

2 June 2018

title

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. (English)

1 reference

2 June 2018

triple-negative breast cancer

1 reference

1 reference

1 reference

A Vincent-Salomon

1 reference

2 June 2018

L Staudacher

1 reference

2 June 2018

P H Cottu

1 reference

2 June 2018

V Diéras

1 reference

2 June 2018

M N Guilhaume

1 reference

2 June 2018

L Escalup

1 reference

2 June 2018

T Dorval

1 reference

2 June 2018

P Beuzeboc

1 reference

2 June 2018

L Mignot

1 reference

2 June 2018

J Y Pierga

1 reference

2 June 2018

publication date

5 October 2010

1 reference

2 June 2018

published in

Annals of Oncology

1 reference

2 June 2018

volume

1 reference

2 June 2018

issue

1 reference

2 June 2018

page(s)

848-856

1 reference

2 June 2018

Global cancer statistics in the year 2000.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

The changing global patterns of female breast cancer incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Triple-negative breast cancer: risk factors to potential targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Triple negative tumours: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Pattern of metastatic spread in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Basal-like breast cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Impact of triple negative phenotype on breast cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Platinum-based chemotherapy in triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ461

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ461

1 reference

2 June 2018

1 reference

2 June 2018